The combination of the two immunotherapy combinations of Shishi Shiguibao has been approved by the FDA

BMS announced that the FDA has approved the PD-1 inhibitor Opdivo (nivolumab), in association with the CTLA-4 inhibitor Yeervoy (ipilimumab), to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorapinib. According to the press release, Opdivo-Yervoy is the first and only dual immunotherapy approved by the FDA for this group of patients. The combination therapy has a potential synergistic mechanism.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. According to statistics, more than 750,000 people worldwide suffer from hepatocellular carcinoma each year, most of them in Asia and almost half in China. HCC is caused mainly by chronic hepatitis caused by hepatitis B or C virus infection, as well as cirrhosis of the liver caused by alcohol consumption or non-alcoholic fatty hepatitis.
Andivo (nivolumab) and Yervoy (ipilimumab) are immuno-checkpoint inhibitors developed by BMS to improve the anti-cancer immune response of T-cells by inhibiting PD-1 and CTLA-4 immune checkpoint proteins, respectively. They have been approved by the FDA to treat other types of cancer, such as metastasis melanoma.FDA approval is based on a Clinical Phase 1/2 study called CheckMate-040. In HCC patients who had previously received Sora noni treatment, 33% (16/49; 95% CI:20-48) were relieved after at least 28 months of follow-up and 8% (4/49) were fully remission (CR). The duration of mitigation (DOR) is 4.6 to 30.5 plus months, of which 88% last at least six months, 56% last at least 12 months and 31% last at least 24 months.
"HCC is an invasive disease that requires different treatments," said Lead researcher, Associate Professor of Clinical Medicine and Phase 1 Clinical Director Dr. Anthony B. El-Khoueiry of the Keck School of Medicine and Norris Comprehensive Cancer Center at the University of Southern California (USC). " we congratulate Opdivo and Yervoy on their approval of the new adaptation, providing new treatment options and more hope for HCC patients who have previously received Soraphini.
(
medicine Mingkangde
)